Profile data is unavailable for this security.
About the company
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicine to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company’s products for HIV/AIDS patients include Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Stribild. The Company’s COVID-19 product is Veklury. The Company’s also provides Epclusa, Harvoni, Vemlidy, and Viread products for liver diseases. The products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy, and Zydelig. The Company’s other products include Letairis (ambrisentan), Ranexa (ranolazine), Cayston, Jyseleca, and AmBisome (amphotericin B liposome for injection). The Company also sells and distributes generic versions of Epclusa and Harvoni in the United States. The Company is also focused on restoring immune balance with agonists targeting immune inhibitory receptors.
- Revenue in USD (TTM)27.28bn
- Net income in USD4.59bn
- Incorporated1987
- Employees17.00k
- LocationGilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
- Phone+1 (650) 574-3000
- Fax+1 (650) 578-9264
- Websitehttps://www.gilead.com/
Mergers & acquisitions
| Acquired company | GILD:NSQ since announced | Transaction value |
|---|---|---|
| MiroBio Ltd | 33.24% | 405.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moderna Inc | 19.26bn | 8.36bn | 59.23bn | 3.90k | 7.69 | 3.09 | 6.80 | 3.07 | 19.96 | 19.96 | 46.31 | 49.67 | 0.7625 | 4.53 | 8.45 | 4,939,231.00 | 33.10 | 38.59 | 45.85 | 58.05 | 71.88 | -- | 43.41 | 48.84 | 2.54 | -- | 0.0531 | 0.00 | 4.29 | 147.88 | -31.47 | -- | 46.94 | -- |
| Zoetis Inc | 8.08bn | 2.11bn | 77.13bn | 13.80k | 37.03 | 17.52 | 29.94 | 9.55 | 4.49 | 4.49 | 17.19 | 9.50 | 0.5606 | 1.15 | 6.88 | 585,507.30 | 14.65 | 14.06 | 17.69 | 16.51 | 69.73 | 69.28 | 26.13 | 25.02 | 1.63 | 12.66 | 0.6422 | 24.62 | 3.91 | 8.77 | 3.78 | 14.46 | 21.21 | 24.14 |
| Vertex Pharmaceuticals Incorporated | 8.93bn | 3.32bn | 81.00bn | 4.80k | 24.58 | 5.82 | 23.34 | 9.07 | 12.82 | 12.82 | 34.47 | 54.13 | 0.5655 | 2.66 | 6.93 | 1,860,563.00 | 21.04 | 19.92 | 24.88 | 23.81 | 87.90 | 87.71 | 37.20 | 33.69 | 4.66 | 72.86 | 0.03 | 0.00 | 17.91 | 29.12 | 41.84 | 66.04 | -4.63 | -- |
| Regeneron Pharmaceuticals Inc | 12.17bn | 4.34bn | 89.83bn | 11.85k | 21.49 | 3.97 | 19.05 | 7.38 | 38.24 | 38.24 | 107.25 | 206.79 | 0.4455 | 0.7169 | 2.14 | 1,027,162.00 | 15.88 | 23.17 | 18.24 | 26.93 | 87.18 | 87.66 | 35.64 | 39.79 | 4.29 | 254.80 | 0.1065 | -- | -24.26 | 15.70 | -46.28 | 23.26 | 42.77 | -- |
| Gilead Sciences, Inc. | 27.28bn | 4.59bn | 103.61bn | 17.00k | 22.81 | 4.87 | 15.41 | 3.80 | 3.64 | 3.64 | 21.62 | 17.03 | 0.4161 | 3.62 | 5.89 | 1,604,765.00 | 6.96 | 6.60 | 8.43 | 7.93 | 79.26 | 78.72 | 16.74 | 17.51 | 1.15 | 6.30 | 0.5433 | 78.18 | -0.0879 | 0.8836 | -26.23 | -14.62 | 4.29 | 7.02 |
| Amgen, Inc. | 26.32bn | 6.55bn | 129.09bn | 25.20k | 19.95 | 35.26 | 12.95 | 4.90 | 12.12 | 12.12 | 48.66 | 6.86 | 0.4169 | 1.42 | 5.03 | 1,044,564.00 | 10.38 | 11.14 | 13.32 | 13.81 | 75.66 | 77.99 | 24.89 | 28.79 | 1.10 | 7.21 | 0.9141 | 53.53 | 1.32 | 2.87 | 11.18 | -4.10 | 7.11 | 11.03 |
| Bristol-Myers Squibb Co | 46.16bn | 6.33bn | 145.78bn | 34.30k | 23.48 | 4.63 | 8.77 | 3.16 | 2.95 | 2.95 | 21.51 | 14.97 | 0.4479 | 4.54 | 5.72 | 1,345,744.00 | 6.16 | 2.80 | 7.82 | 3.45 | 78.18 | 75.49 | 13.75 | 6.98 | 1.14 | 6.39 | 0.5582 | 148.90 | -0.4872 | 17.31 | -9.54 | 10.14 | 1.17 | 6.72 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2022 | 106.63m | 8.50% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 87.61m | 6.99% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2022 | 68.89m | 5.49% |
| SSgA Funds Management, Inc.as of 31 Dec 2022 | 58.94m | 4.70% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2022 | 54.60m | 4.35% |
| Dodge & Coxas of 31 Dec 2022 | 35.89m | 2.86% |
| Geode Capital Management LLCas of 31 Dec 2022 | 23.85m | 1.90% |
| BlackRock Advisors (UK) Ltd.as of 31 Dec 2022 | 14.18m | 1.13% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2022 | 14.00m | 1.12% |
| Norges Bank Investment Managementas of 31 Dec 2022 | 12.99m | 1.04% |
